HRP20211621T1 - Imatinib za uporabu u liječenju moždanog udara - Google Patents
Imatinib za uporabu u liječenju moždanog udara Download PDFInfo
- Publication number
- HRP20211621T1 HRP20211621T1 HRP20211621TT HRP20211621T HRP20211621T1 HR P20211621 T1 HRP20211621 T1 HR P20211621T1 HR P20211621T T HRP20211621T T HR P20211621TT HR P20211621 T HRP20211621 T HR P20211621T HR P20211621 T1 HRP20211621 T1 HR P20211621T1
- Authority
- HR
- Croatia
- Prior art keywords
- imatinib
- administered
- day
- use according
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (en) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
| EP17760399.0A EP3423060B1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| PCT/SE2017/050183 WO2017151043A1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211621T1 true HRP20211621T1 (hr) | 2022-02-04 |
Family
ID=59744327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211621TT HRP20211621T1 (hr) | 2016-02-29 | 2017-02-27 | Imatinib za uporabu u liječenju moždanog udara |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953010B2 (enExample) |
| EP (1) | EP3423060B1 (enExample) |
| JP (1) | JP6914957B2 (enExample) |
| CN (2) | CN119523986A (enExample) |
| AU (1) | AU2017227515B2 (enExample) |
| DK (1) | DK3423060T3 (enExample) |
| ES (1) | ES2895432T3 (enExample) |
| HR (1) | HRP20211621T1 (enExample) |
| HU (1) | HUE056798T2 (enExample) |
| LT (1) | LT3423060T (enExample) |
| PL (1) | PL3423060T3 (enExample) |
| PT (1) | PT3423060T (enExample) |
| RS (1) | RS62465B1 (enExample) |
| RU (1) | RU2739382C1 (enExample) |
| SE (1) | SE539450C2 (enExample) |
| SI (1) | SI3423060T1 (enExample) |
| WO (1) | WO2017151043A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| CN114306342B (zh) * | 2020-09-30 | 2024-06-28 | 江苏先声药业有限公司 | 一种注射用伊马替尼盐的药物组合物及其制备方法 |
| CN118524852A (zh) * | 2021-11-09 | 2024-08-20 | 真和制药有限公司 | 治疗或抑制心血管疾病的方法 |
| EP4311539A1 (en) | 2022-07-29 | 2024-01-31 | Artorange Ltd. | Imatinib formulation for parenteral administration |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| EP2021028A2 (en) | 2006-04-17 | 2009-02-11 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
| US7977348B2 (en) * | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
| EP2076507A2 (en) * | 2006-10-26 | 2009-07-08 | Sicor, Inc. | Imatinib base, and imatinib mesylate and processes for preparation thereof |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| TR201911199T4 (tr) * | 2009-03-27 | 2019-08-21 | Moleac Pte Ltd | Hücre büyümesini arttırmak için tedavi. |
-
2016
- 2016-02-29 SE SE1650260A patent/SE539450C2/en not_active IP Right Cessation
-
2017
- 2017-02-27 CN CN202411509669.3A patent/CN119523986A/zh active Pending
- 2017-02-27 US US16/080,529 patent/US10953010B2/en active Active
- 2017-02-27 LT LTEPPCT/SE2017/050183T patent/LT3423060T/lt unknown
- 2017-02-27 SI SI201730931T patent/SI3423060T1/sl unknown
- 2017-02-27 HU HUE17760399A patent/HUE056798T2/hu unknown
- 2017-02-27 DK DK17760399.0T patent/DK3423060T3/da active
- 2017-02-27 HR HRP20211621TT patent/HRP20211621T1/hr unknown
- 2017-02-27 JP JP2018545843A patent/JP6914957B2/ja active Active
- 2017-02-27 RU RU2019122730A patent/RU2739382C1/ru active
- 2017-02-27 WO PCT/SE2017/050183 patent/WO2017151043A1/en not_active Ceased
- 2017-02-27 PL PL17760399T patent/PL3423060T3/pl unknown
- 2017-02-27 ES ES17760399T patent/ES2895432T3/es active Active
- 2017-02-27 CN CN201780013732.6A patent/CN108697711A/zh active Pending
- 2017-02-27 RS RS20211286A patent/RS62465B1/sr unknown
- 2017-02-27 PT PT177603990T patent/PT3423060T/pt unknown
- 2017-02-27 EP EP17760399.0A patent/EP3423060B1/en active Active
- 2017-02-27 AU AU2017227515A patent/AU2017227515B2/en active Active
-
2021
- 2021-02-26 US US17/186,303 patent/US20210236488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT3423060T (pt) | 2021-10-20 |
| RS62465B1 (sr) | 2021-11-30 |
| AU2017227515B2 (en) | 2022-03-24 |
| ES2895432T3 (es) | 2022-02-21 |
| JP2019507165A (ja) | 2019-03-14 |
| SE539450C2 (en) | 2017-09-26 |
| LT3423060T (lt) | 2021-11-10 |
| CN108697711A (zh) | 2018-10-23 |
| RU2739382C1 (ru) | 2020-12-23 |
| JP6914957B2 (ja) | 2021-08-04 |
| CN119523986A (zh) | 2025-02-28 |
| EP3423060B1 (en) | 2021-07-21 |
| US10953010B2 (en) | 2021-03-23 |
| DK3423060T3 (da) | 2021-10-25 |
| SE1650260A1 (en) | 2017-08-30 |
| WO2017151043A1 (en) | 2017-09-08 |
| AU2017227515A1 (en) | 2018-08-30 |
| EP3423060A1 (en) | 2019-01-09 |
| SI3423060T1 (sl) | 2021-11-30 |
| US20210236488A1 (en) | 2021-08-05 |
| HUE056798T2 (hu) | 2022-03-28 |
| EP3423060A4 (en) | 2020-01-01 |
| US20190030030A1 (en) | 2019-01-31 |
| PL3423060T3 (pl) | 2022-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211621T1 (hr) | Imatinib za uporabu u liječenju moždanog udara | |
| Wang et al. | Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review | |
| CO6361942A2 (es) | Terapia de combinacion con epoxicetonas peptidicas | |
| MX2022015499A (es) | Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| CO6260078A2 (es) | Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros | |
| MX2018003028A (es) | Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc). | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| MX2017005350A (es) | Terapia para la inhibicion de la replicacion del virus de arn monocatenario. | |
| MX2018009173A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash). | |
| AR062658A1 (es) | Terapias de combinacion para artritis reumatoide | |
| CL2021001976A1 (es) | Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular | |
| AR120399A1 (es) | Un método de tratamiento de un cáncer positivo para dll3 | |
| AR040792A1 (es) | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| UY39503A (es) | Formulación sólida | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
| AR116592A1 (es) | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib | |
| Yari et al. | The efficacy of adding dexamethazone to clomiphene citrate in the treatment of polycystic ovary syndrome and infertility | |
| CL2022000179A1 (es) | Terapia contra la ibd mediante inhibición de drd3 en linfocitos t reguladores |